Your browser doesn't support javascript.
loading
Apigenin in cancer therapy: Prevention of genomic instability and anticancer mechanisms.
Moslehi, Masoud; Rezaei, Sepideh; Talebzadeh, Pourya; Ansari, Mohammad Javed; Jawad, Mohammed Abed; Jalil, Abduladheem Turki; Rastegar-Pouyani, Nima; Jafarzadeh, Emad; Taeb, Shahram; Najafi, Masoud.
Affiliation
  • Moslehi M; Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Rezaei S; Department of Chemistry, University of Houston, Houston, Texas, USA.
  • Talebzadeh P; Student Research Committee, Tehran Medical Faculty, Islamic Azad University, Tehran, Iran.
  • Ansari MJ; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj, Saudi Arabia.
  • Jawad MA; Department of Pharmacy, Al-Nisour University College, Baghdad, Iraq.
  • Jalil AT; Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, Iraq.
  • Rastegar-Pouyani N; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Jafarzadeh E; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Taeb S; Department of Radiology, School of Paramedical Sciences, Guilan University of Medical Sciences, Rasht, Iran.
  • Najafi M; Medical Biotechnology Research Center, School of Paramedical Sciences, Guilan University of Medical Sciences, Rasht, Iran.
Clin Exp Pharmacol Physiol ; 50(1): 3-18, 2023 01.
Article in En | MEDLINE | ID: mdl-36111951
The incidence of cancer has been growing worldwide. Better survival rates following the administration of novel drugs and new combination therapies may concomitantly cause concern regarding the long-term adverse effects of cancer therapy, for example, second primary malignancies. Moreover, overcoming tumour resistance to anticancer agents has been long considered as a critical challenge in cancer research. Some low toxic adjuvants such as herb-derived molecules may be of interest for chemoprevention and overcoming the resistance of malignancies to cancer therapy. Apigenin is a plant-derived molecule with attractive properties for chemoprevention, for instance, promising anti-tumour effects, which may make it a desirable adjuvant to reduce genomic instability and the risks of second malignancies among normal tissues. Moreover, it may improve the efficiency of anticancer modalities. This paper aims to review various effects of apigenin in both normal tissues and malignancies. In addition, we explain how apigenin may have the ability to protect usual cells against the genotoxic repercussions following radiotherapy and chemotherapy. Furthermore, the inhibitory effects of apigenin on tumours will be discussed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Apigenin / Neoplasms Limits: Humans Language: En Journal: Clin Exp Pharmacol Physiol Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Apigenin / Neoplasms Limits: Humans Language: En Journal: Clin Exp Pharmacol Physiol Year: 2023 Document type: Article Affiliation country: Country of publication: